Together, these data indicate that ZMYND8 is overexpressed in a subset of ccRCC, and that its overexpression is associated with poor clinical outcome in ccRCC patients with VHL deficiency. Here, ZMYND8 is linked to nonpapillary renal cell carcinoma.